Swiss National Bank Purchases 3,200 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Swiss National Bank lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 437,500 shares of the biopharmaceutical company’s stock after purchasing an additional 3,200 shares during the quarter. Swiss National Bank’s holdings in Amicus Therapeutics were worth $4,121,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Amicus Therapeutics in the third quarter worth $55,000. R Squared Ltd acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at $79,000. KBC Group NV raised its stake in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 3,120 shares in the last quarter. Stephens Inc. AR bought a new position in shares of Amicus Therapeutics during the 4th quarter worth about $101,000. Finally, AlphaQuest LLC boosted its position in shares of Amicus Therapeutics by 635.1% during the 4th quarter. AlphaQuest LLC now owns 10,732 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 9,272 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on FOLD. Wells Fargo & Company dropped their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $8.62 on Wednesday. The business’s fifty day moving average is $9.33 and its two-hundred day moving average is $10.01. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The firm has a market cap of $2.65 billion, a P/E ratio of -47.89, a P/E/G ratio of 1.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a 52 week low of $8.52 and a 52 week high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.